1610413-97-2

Basic information

• Product Name: 2-(4-((9S,13S)-9,13-Bis(Tert-Butoxycarbonyl)-18,18-Dimethyl-3,11,16-Trioxo-17-Oxa-2,4,10,12-Tetraazanonadecyl)Phenyl)Acetic Acid
• Synonyms: 2-(4-((9S,13S)-9,13-Bis(Tert-Butoxycarbonyl)-18,18-Dimethyl-3,11,16-Trioxo-17-Oxa-2,4,10,12-Tetraazanonadecyl)Phenyl)Acetic Acid
• CAS NO: 1610413-97-2
• Molecular Formula: C₃₄H₅₄N₄O₁₀
• Molecular Weight: 678.81336
• Product Categories: ADCs;ADC
• Mol File: 1610413-97-2.mol

Chemical Properties

• Boiling Point: 837.7±65.0 °C(Predicted)
• Appearance: /
• Density: 1.156±0.06 g/cm3(Predicted)
• PKA: 4.34±0.10(Predicted)
• CAS DataBase Reference: 2-(4-((9S,13S)-9,13-Bis(Tert-Butoxycarbonyl)-18,18-Dimethyl-3,11,16-Trioxo-17-Oxa-2,4,10,12-Tetraazanonadecyl)Phenyl)Acetic Acid(CAS DataBase Reference)
• NIST Chemistry Reference: 2-(4-((9S,13S)-9,13-Bis(Tert-Butoxycarbonyl)-18,18-Dimethyl-3,11,16-Trioxo-17-Oxa-2,4,10,12-Tetraazanonadecyl)Phenyl)Acetic Acid(1610413-97-2)
• EPA Substance Registry System: 2-(4-((9S,13S)-9,13-Bis(Tert-Butoxycarbonyl)-18,18-Dimethyl-3,11,16-Trioxo-17-Oxa-2,4,10,12-Tetraazanonadecyl)Phenyl)Acetic Acid(1610413-97-2)

Safety Data

• Hazardous Substances Data: 1610413-97-2(Hazardous Substances Data)

Usage

Uses

Used in Organic Chemistry:
2-(4-((9S,13S)-9,13-Bis(Tert-Butoxycarbonyl)-18,18-Dimethyl-3,11,16-Trioxo-17-Oxa-2,4,10,12-Tetraazanonadecyl)Phenyl)Acetic Acid is used as a building block for the synthesis of more complex organic molecules due to its multiple functional groups and unique structure.
Used in Pharmaceutical Industry:
2-(4-((9S,13S)-9,13-Bis(Tert-Butoxycarbonyl)-18,18-Dimethyl-3,11,16-Trioxo-17-Oxa-2,4,10,12-Tetraazanonadecyl)Phenyl)Acetic Acid is used as a potential drug candidate for the development of new therapeutic agents, given its complex structure and functional groups that may exhibit biological activity.
Used in Research:
2-(4-((9S,13S)-9,13-Bis(Tert-Butoxycarbonyl)-18,18-Dimethyl-3,11,16-Trioxo-17,17-Oxa-2,4,10,12-Tetraazanonadecyl)Phenyl)Acetic Acid is used as a research tool to study the properties and behavior of complex organic compounds, as well as to explore its potential applications in various fields.

Upstream product

• 5978-22-3 N(ε)-benzoyloxycarbonyl-L-lysine tert-butyl ester hydrochloride 
• 1025796-31-9 (S)-2-[3-((S)-5-amino-1-tert-butoxycarbonylpentyl)ureido]pentanedioic acid di-tert-butyl ester 
• 1200-05-1 2-(4-(aminomethyl)phenyl)acetic acid 
• 7693-46-1 4-Nitrophenyl chloroformate 
• 1025796-30-8 (S)-2-[3-((S)-(5-benzyloxycarbonylamino)-1-tert-butoxycarbonylpentyl)ureido]pentanedioic acid di-tert-butyl ester 
• 32677-01-3 L-glutamic acid di-tert-butyl ester hydrochloride 
• 156079-00-4 di-tert-butyl <<(4-nitrophenyl)oxy>carbonyl>-L-glutamate 
• 1610413-98-3 C₃₁H₄₈N₄O₁₁ 
• 71420-92-3 2-(4-(((tert-butoxycarbonyl)amino)methyl)phenyl)acetic acid 

Downstream Products

• 1610414-00-0 C₃₃H₄₅N₇O₁₇S 

Relevant articles and documents

METHODS OF TREATING CANCER WITH A PSMA LIGAND-TUBULYSIN COMPOUND

The invention described herein pertains to drug delivery conjugates for targeted therapy. The invention described herein relates to methods of treating PSMA expressing cancers with a PSMA ligand-tubulysin compound. The invention described herein also relates to methods of treating PSMA-expressing cancers with a PSMA ligand-tubulysin compound in patients where stable disease results after treatment with the PSMA ligand-tubulysin compound.

METHODS OF TREATING CANCER WITH A PSMA LIGAND-TUBULYSIN COMPOUND

The invention described herein pertains to drug delivery conjugates for targeted therapy. The invention described herein relates to methods of treating PSMA expressing cancers with a PSMA ligand-tubulysin compound. The invention described herein also relates to methods of treating PSMA-expressing cancers with a PSMA ligand-tubulysin compound in patients where stable disease results after treatment with the PSMA ligand-tubulysin compound.

CONJUGATES FOR TREATING DISEASES CAUSED BY PSMA EXPRESSING CELLS

The invention described herein pertains to the diagnosis, imaging, and/or treatment of pathogenic cell populations. In particular, the invention described herein pertains to the diagnosis, imaging, and/or treatment of diseases caused by PSMA expressing cells, such as prostate cancer cells, using compounds capable of targeting PSMA expressing cells.